Sana Biotechnology, Inc. (SANA) Stock

Sana Biotechnology, Inc. (SANA) is a Healthcare stock trading at $3.75 (as of 2026-08-20), with a market capitalization of $1.12B. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Sana Biotechnology, Inc. develops cell-based therapies by engineering cells for use as medicines, using both ex vivo and in vivo platform approaches. Its programs target multiple therapeutic areas and include candidates such as SG295/SG242 for CD19+ cancers, SG221/SG239 and related programs for multiple myeloma, SG418 and other candidates for genetic blood disorders, and therapies for diseases including type I diabetes and central nervous system disorders.

Valuation — source: SEC EDGAR (first-party)
Price$3.75
Market Cap$1.12B
Price / Book7.26
FCF Yield-23.0%
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.6
Industry P/E (Pharmaceutical Products)17.2
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderFMR LLC ($107.80M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOSteven D. Harr
Employees194
CountryUS
IPO Date2021-02-04

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Inhibrx Biosciences, Inc. (INBX)
  • MeiraGTx Holdings plc (MGTX)
  • Cullinan Therapeutics, Inc. (CGEM)
  • Monte Rosa Therapeutics, Inc. (GLUE)
  • Vor Biopharma Inc. (VOR)
  • Odyssey Therapeutics, Inc. (ODTX)
  • Candel Therapeutics, Inc. (CADL)
  • Solid Biosciences Inc. (SLDB)
SANA earnings history · SANA institutional & insider holders · SANA KPIs & operating metrics · SANA financials · SANA investor presentations & press releases · SANA SEC filings · SANA peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-20.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.